HU-308 (also known as onternabez, HU308, PPP-003 and ARDS-003) is a cannabidiol (CBD)-derivative drug[citation needed] that acts as a potent cannabinoid agonist. It is highly selective for the cannabinoid-2 receptor (CB2 receptor) subtype, with a selectivity more than 5,000 times greater for the CB2 receptor than the CB1 receptor.[1][2][3] The synthesis and characterization of HU-308 took place in the laboratory of Raphael Mechoulam at the Hebrew University of Jerusalem (the HU in HU-308) in the late 1990s. The pinene dimethoxy-DMH-CBD derivative HU-308 was identified as a potent peripheral CB2-selective agonist in in vitro and animal studies in 1990[1] and 1999.[2]
Legal status | |
---|---|
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Excretion | Kidneys |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C27H42O3 |
Molar mass | 414.630 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
Tetra Bio-Pharma owns the intellectual property rights to HU-308.[4][5]
HU-308 is non-psychoactive and not scheduled at the federal level in the United States.[6] It is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess there.[7]